• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Cyclerion Therapeutics, Inc. (CYCN) Stock Price, News & Analysis

Cyclerion Therapeutics, Inc. (CYCN) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.66

-$1.66

(-31.2%)

Day's range
$3.33
Day's range
$5.45
50-day range
$1.27
Day's range
$9.47
  • Country: US
  • ISIN: US23255M2044
52 wk range
$1.27
Day's range
$9.47


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -35.57
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (CYCN)
  • Company Cyclerion Therapeutics, Inc.
  • Price $3.66
  • Changes Percentage (-31.2%)
  • Change -$1.66
  • Day Low $3.33
  • Day High $5.45
  • Year High $9.47

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/03/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$4.55
  • Trailing P/E Ratio -0.56
  • Forward P/E Ratio -0.56
  • P/E Growth -0.56
  • Net Income $-21,015,000

Income Statement

Quarterly

Annual

Latest News of CYCN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Cyclerion Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of CYCN in the last quarter?

    In the last quarter Cyclerion Therapeutics, Inc. earnings were on Thursday, November, 3rd. The Cyclerion Therapeutics, Inc. maker reported -$4.80 EPS for the quarter, beating analysts' consensus estimates of -$7.00 by $2.20.

  • What is the Cyclerion Therapeutics, Inc. stock price today?

    Today's price of Cyclerion Therapeutics, Inc. is $3.66 — it has decreased by -31.2% in the past 24 hours. Watch Cyclerion Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Cyclerion Therapeutics, Inc. release reports?

    Yes, you can track Cyclerion Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Cyclerion Therapeutics, Inc. stock forecast?

    Watch the Cyclerion Therapeutics, Inc. chart and read a more detailed Cyclerion Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Cyclerion Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Cyclerion Therapeutics, Inc. stock ticker.

  • How to buy Cyclerion Therapeutics, Inc. stocks?

    Like other stocks, CYCN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Cyclerion Therapeutics, Inc.'s EBITDA?

    Cyclerion Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Cyclerion Therapeutics, Inc.’s financial statements.

  • What is the Cyclerion Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Cyclerion Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Cyclerion Therapeutics, Inc.'s financials relevant news, and technical analysis. Cyclerion Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Cyclerion Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Cyclerion Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Cyclerion Therapeutics, Inc. for its last quarter?

    Cyclerion Therapeutics, Inc. published it's last quarterly revenues at $194,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.